- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06202157
Metabolic Differences Between Dihydroberberine and Micellar Berberine
January 2, 2024 updated by: Factors Group of Nutritional Companies Inc.
Metabolic Differences Between Dihydroberberine and Micellar Berberine in Humans
Differences in metabolites of dihydroberberine (DHB) and micellar berberine (LipoMicel®, LMB) are investigated through a randomized study involving human volunteers.
Over a 24-hour period, blood samples are collected and subjected to Ultra High-Performance Liquid Chromatography-High Resolution Mass Spectrometry (UHPLC-HRMS) analysis to quantify the concentrations of berberine and its metabolites.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Burnaby, British Columbia, Canada, V3N 4S9
- ISURA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 21 or older
- healthy, good physical condition
Exclusion Criteria:
- Pregnancy or breast-feeding
- Gastrointestinal conditions
- Acute or chronic liver disease
- Acute or chronic kidney disease
- Acute or chronic cardiovascular disease
- Hematological disease
- Diabetes
- Allergy or Intolerance to gluten
- Allergy or Intolerance to Berberine
- Use of any form of nicotine or tobacco
- Alcohol and substance abuse history
- Use of medications (e.g., blood sugar-lowering agents, or statins)
- Use of Berberine supplements
- Participation in another investigational study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LMB (LipoMicel Berberine)
|
A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
Other Names:
|
Experimental: DHB (Dihydroberberine)
|
A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC: the area under the concentration-time curve
Time Frame: at baseline (t=0 hours; before intervention), at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
|
For each berberine metabolite, PK parameters such as Area Under Curve (AUC) of the blood concentrations over a 24-hour period are reported.
|
at baseline (t=0 hours; before intervention), at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
|
Cmax: the maximum blood concentration
Time Frame: at baseline (t=0 hours; before intervention), at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
|
For each berberine metabolite, PK parameters such as the maximum blood concentration (Cmax) are reported.
|
at baseline (t=0 hours; before intervention), at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
|
Tmax: the time at which Cmax is reached
Time Frame: at baseline (t=0 hours; before intervention), at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
|
For each berberine metabolite, PK parameters such as Tmax, the time at which Cmax is reached, are reported.
|
at baseline (t=0 hours; before intervention), at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2023
Primary Completion (Actual)
December 31, 2023
Study Completion (Actual)
December 31, 2023
Study Registration Dates
First Submitted
January 2, 2024
First Submitted That Met QC Criteria
January 2, 2024
First Posted (Actual)
January 11, 2024
Study Record Updates
Last Update Posted (Actual)
January 11, 2024
Last Update Submitted That Met QC Criteria
January 2, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- RR401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phase I and Phase II Metabolites of Berberine
-
AstraZenecaActive, not recruitingPhase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaChina
-
Samsung Medical CenterTerminatedPhase I: To Determine the Maximum Tolerated Dose (MTD) | Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/OxaliplatinKorea, Republic of
-
Novartis PharmaceuticalsTerminatedSolid Tumors for Phase Ib | Pancreatic Cancer for Phase II | Colorectal Cancer for Phase IIUnited States, Canada, Australia, Belgium, Germany, Netherlands, Spain
-
University Health Network, TorontoPrincess Margaret Hospital, Canada; Ontario Institute for Cancer ResearchCompletedBreast Cancer | Colorectal Cancer | Metastatic | Gynecological Cancer | Melanoma Cancer | Eligible for Phase I or Phase II StudyCanada
-
The Lymphoma Academic Research OrganisationCompletedFollicular Lymphoma Patients (Phase IB) | Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)France, Belgium
-
National Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Disease | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase of Disease | Chronic Phase of DiseaseUnited States, Germany, Italy
-
Pusan National University HospitalPusan National University Yangsan HospitalUnknownElective Surgery of Gastrointestinal Tract | 100 Adults Aged Between 20 and 70 Years Old | ASA Physical Status of I or IIKorea, Republic of
-
University Hospital, BordeauxCompletedImpairment of Gastric Emptying | Acute Phase of Myocardial InfarctionFrance
Clinical Trials on LMB
-
National Cancer Institute (NCI)CompletedLymphoma | Cutaneous | T-CellUnited States
-
National Cancer Institute (NCI)CompletedLeukemia | Chronic | LymphocyticUnited States
-
National Cancer Institute (NCI)Terminated
-
National Cancer Institute (NCI)TerminatedMesotheliomaUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Lung Cancer | Bladder CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompleted
-
National Cancer Institute (NCI)CompletedLymphoma | LeukemiaUnited States
-
University Hospital FreiburgNational Cancer Institute (NCI)UnknownGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal CancerGermany
-
University of Maryland, BaltimoreNational Cancer Institute (NCI)CompletedBreast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder CancerUnited States